Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Solid Tumors × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 90 Carcinoma, Non-Small-Cell Lung 28 Carcinoma, Renal Cell 19 Prostatic Neoplasms 13 Neoplasm Metastasis 13 Lung Neoplasms 11 Brain Neoplasms 11 Neoplasms 10 Breast Neoplasms 10 Uveal Melanoma 9 Sarcoma 8 Pancreatic Neoplasms 7 Urinary Bladder Neoplasms 6 Small Cell Lung Carcinoma 6 Kidney Neoplasms 6 Carcinoma, Transitional Cell 6 Skin Neoplasms 5 Carcinoma, Hepatocellular 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Colorectal Neoplasms 4 Urogenital Neoplasms 3 Triple Negative Breast Neoplasms 3 Recurrence 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Neuroendocrine Tumors 3 Mesothelioma, Malignant 3 Mesothelioma 3

Interventions

Paclitaxel 2 Injections 2 tislelizumab 1 osimertinib 1 lazertinib 1 fluzoparib 1 camrelizumab 1 PM 01183 1 Nivolumab 1 Ipilimumab 1 HMPL-013 1 Erlotinib Hydrochloride 1 Dexamethasone 1 Calcium Dobesilate 1 Bortezomib 1 Bevacizumab 1 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡